Gunn, Nadege T.
Pinnacle Clinical Research
4 papers on CoChatORCID 0000-0003-3118-3690
Most cited papers
- Verified
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Loomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 296
- Verified
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 280
- Verified
Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
Loomba, R., Noureddin, M., Kowdley, K., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N. T., Caldwell, S., Goodman, Z., et al. (2020) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentOrgan Transplantation Techniques and Outcomes
Cited by 9
- Verified
Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
Harrison, S. A., Neff, G., Guy, C., Bashir, M., Paredes, A., Frias, J., Younes, Z. H., Trotter, J. F., Gunn, N. T., Moussa, S., et al. (2020) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 1
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free